Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined Neurosurgical and Gastrointestinal Surgical Approach Using Omental Flap for Adult Currarino Syndrome: A Case Report.

NMC case report journal·2026
Same author

Bilateral intradiploic dermoid cysts with unilateral rupture causing hearing loss: illustrative case.

Journal of neurosurgery. Case lessons·2026
Same author

Efficacy Endpoint Standardization in Adult Primary CNS Tumor Trials: Integrating Regulatory Science and Clinical Perspectives in the RANO 2.0 Era.

Cancers·2026
Same author

Possible involvement of genome-wide near-haploidy and <i>MEN1</i> mutation in the molecular pathogenesis of pituitary carcinoma: Analysis by whole exome sequencing.

Neuro-oncology advances·2026
Same author

Association between time to surgery and survival in patients with initially diagnosed WHO 2021 grade 4 gliomas.

Neuro-oncology advances·2026
Same author

Spontaneous regression of peritumoral brain edema in an asymptomatic meningioma: A radiological case report.

Radiology case reports·2026

Related Experiment Video

Updated: May 22, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Adoptive cell transfer therapy for malignant gliomas.

Eiichi Ishikawa1, Shingo Takano, Tadao Ohno

  • 1Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.

Advances in Experimental Medicine and Biology
|May 29, 2012
PubMed
Summary

Adoptive cell therapy shows promise for malignant gliomas, with natural killer (NK) cells offering potential, especially when combined with vaccines. Further research is needed for high-dose chemotherapy combined with cell transfer.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: May 22, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

  • Oncology
  • Immunology
  • Cell Therapy

Background:

  • Malignant gliomas remain challenging to treat with conventional therapies.
  • Adoptive cell therapy has been explored using various effector cells since the late 1980s.
  • Early approaches included lymphokine-activated killer (LAK) cells and later, tumor-specific cytotoxic T-lymphocytes (CTLs).

Purpose of the Study:

  • To review the evolution and efficacy of adoptive cell therapies for malignant gliomas.
  • To evaluate the potential of different cell types, including natural killer (NK) cells, in glioma treatment.
  • To discuss novel strategies like combining cell therapy with vaccines or high-dose chemotherapy.

Main Methods:

  • Review of clinical studies and therapeutic protocols involving adoptive cell transfer for malignant gliomas.
  • Analysis of different effector cell types: LAK cells, CTLs, and NK cells.
  • Examination of combination therapies, including autologous tumor vaccines (ATV) and high-dose chemotherapy.

Main Results:

  • Adoptive cell therapies have demonstrated the ability of ex vivo expanded effector cells to kill glioma cells in vivo.
  • While some studies show radiologic tumor shrinkage, cell transfer alone has limitations due to cost and short-term efficacy.
  • Natural killer (NK) cell therapy shows potential due to ease of expansion and synergy with vaccine therapy.

Conclusions:

  • Adoptive cell therapy, particularly NK cell therapy, holds promise for malignant gliomas, especially when integrated with other treatment modalities like vaccines.
  • High-dose chemotherapy followed by large-scale cell transfer therapy warrants further investigation as a potential new strategy.
  • Optimizing cell expansion, in vivo persistence, and combination protocols are crucial for advancing adoptive cell therapy for gliomas.